Celgene Corp. (CELG) said it will stop a study of its top-selling blood-cancer pill Revlimid as a treatment for prostate tumors because the drug failed to help patients more than chemotherapy and steroids alone.
A data-monitoring panel recommended ending the late-stage clinical trial, called Mainsail, after finding the drug wouldn’t meet the primary goal of prolonging survival in patients with castrate-resistant prostate cancer, Celgene said today in a statement.
Revlimid, approved for multiple myeloma and anemia, generated $2.5 billion in revenue last year for Summit, New Jersey-based Celgene. Sales of the drug, also known as lenalidomide, may surpass $3.8 billion next year, according to the average estimate of 11 analysts surveyed by Bloomberg. The trial evaluated the pill’s effectiveness and safety when used for prostate cancer in combination with the chemotherapy drug docetaxel and the steroid prednisone.
Celgene gained less than 1 percent to $61.69 at the close in New York. The shares have advanced 4.3 percent this year.
To contact the reporter on this story: Molly Peterson in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Adriel Bettelheim at email@example.com